Third report of Tysabri-linked PML in commercial setting

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1663, 2008-01, pp. : 20-20

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Third report of Tysabri-linked PML in commercial setting

Reactions Weekly, Vol. 1, Iss. 1227, 2008-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Prior immunosuppressant use ups Tysabri PML risk

Reactions Weekly, Vol. 1, Iss. 1350, 2011-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

No new confirmed cases of progressive multifocal leukoencephalopathy (PML) associated with Tysabri [natalizumab]

Reactions Weekly, Vol. 1, Iss. 1075, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

A possible fifth case of Tysabri [natalizumab]-associated progressive multifocal leukoencephalopathy (PML) has been reported to the US FDA.

Reactions Weekly, Vol. 1, Iss. 1057, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

There have been no new cases of progressive multifocal leukoencephalopathy (PML) associated with Tysabri [natalizumab]

Reactions Weekly, Vol. 1, Iss. 1065, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite